Gossamer Bio
GOSS
110 hedge funds and large institutions have $684M invested in Gossamer Bio in 2020 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 60 increasing their positions, 12 reducing their positions, and 14 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 12
164% more call options, than puts
Call options by funds: $1.79M | Put options by funds: $678K
100% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 14
73% more capital invested
Capital invested by funds: $396M → $684M (+$288M)
15% more funds holding
Funds holding: 96 → 110 (+14)
10.43% more ownership
Funds ownership: 58.85% → 69.28% (+10%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$23.7M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$19M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.5M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$12.8M |
| 5 |
AG
Artal Group
Luxembourg
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$12M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.37M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$2.64M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.21M |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$757K |
GOSS Hedge Fund Activity: Q2 2020 in Review
110 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q2 2020, worth a combined $684M — up 73% from $396M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new GOSS positions and 14 closed out — a net gain of 14 holders — while 60 added to existing stakes and 12 trimmed.
The largest buyer was Capital International Investors, adding an estimated $23.7M. The largest seller was Omega Fund Management, cutting an estimated $12M.
- 110 institutional investors held Gossamer Bio (GOSS) as of Q2 2020, up from 96 in Q1 2020.
- Funds reported $684M of Gossamer Bio stock for Q2 2020, up 73% quarter-over-quarter.
- 28 funds opened new Gossamer Bio positions in Q2 2020 and 14 closed out, a net change of +14 holders.
- The largest Gossamer Bio buyer in Q2 2020 was Capital International Investors, an estimated $23.7M added.
- The largest Gossamer Bio seller in Q2 2020 was Omega Fund Management, an estimated $12M sold.
Based on aggregated 13F filings for Q2 2020.